Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis  

作　　者：Marta Consuegra-Fernández Marc Julià Mario Martínez-Florensa Fernando Aranda Cristina Català Noelia Armiger-Borràs María-Teresa Arias Francisca Santiago Antonio Guilabert Anna Esteve Carlos Muñoz Carlos Ferrándiz José-Manuel Carrascosa Edurne Pedrosa Jorge Romaní MercèAlsina José-Manuel Mascaró-Galy Francisco Lozano 

机构地区：[1]Immunoreceptores del Sistema Innat i Adaptatiu,Institut d'Investigacions Biomèdiques August Pi i Sunyer(IDIBAPS),Barcelona 08036,Spain [2]Servicio de Dermatologia,Hospital Universitario de Basurto,Bilbao 48013,Spain [3]Servei d’Immunologia,Centre de Diagnòstic Biomèdic,Hospital Clínic de Barcelona,Barcelona 08036,Spain [4]Servei de Dermatologia,Hospital General de Granollers,Barcelona 08402,Spain [5]Centre d’Estudis Epidemiològics sobre les ITS i Sida de Catalunya(CEEISCAT),ASPC,CIBER Epidemiologia y Salud Pública,Badalona 08916,Spain [6]Servei de Dermatologia,Hospital Universitari Germans Trias i Pujol,Badalona 08916,Spain [7]Laboratori d’Immunobiologia per Investigaciói Aplicacions al Diagnòstic,Banc de Sang i Teixits(BST),Institut d’Investigacióen Ciències de la Salut Germans Trias i Pujol,Departament de Biologia Cel·lular,Fisiologia i Immunologia,Universitat Autònoma de Barcelona,Bellaterra 08193,Spain [8]Servei de Dermatologia,Consorci Sanitari Parc Taulí,08208 Sabadell.Universitat Autónoma de Barcelona,Bellaterra 08193,Spain [9]Servei de Dermatologia,Hospital Clínic de Barcelona,Barcelona 08036,Spain [10]Departament de Biomedicina,Universitat de Barcelona,Barcelona 08036,Spain

出　　处：《Cellular & Molecular Immunology》2018年第10期898-906,共9页中国免疫学杂志（英文版）

基　　金：supported by grants from the Spanish Ministerio de Economía y Competitividad(Plan Nacional I+D+i,SAF2013-46151-R and SAF2016-80535-R to FL),co-financed by the European Development Regional Fund‘A way to achieve Europe’ERDF;supported by the Sara Borrell fellowship CD15/00016 from Instituto de Salud Carlos Ⅲ.

摘　　要：Psoriasis is a chronic inflammatory skin disease with a strong genetic background and is triggered by environmental factors.Available evidence supports CD6,a lymphocyte surface receptor mostly expressed by T cells,as a putative target in autoimmunity.Accordingly,a humanized anti-CD6 antibody has been assayed for the treatment of certain autoimmune disorders,including psoriasis.Here,we present novel evidence in mice and humans for a direct involvement of CD6 in psoriasis pathophysiology.First,an attenuated form of imiquimod-induced psoriasis-like skin inflammation was demonstrated in CD6-deficient mice,as deduced from lower epidermal thickness and local reduced production of pro-inflammatory cytokines,namely,interleukin-17A.Thus,isolated CD4+CD62L+T cells from CD6-deficient mice displayed decreased in vitro T-helper type 17 polarization.Second,a statistically significant association between CD6 single-nucleotide polymorphisms(rs17824933,rs11230563 and rs12360861)and more severe forms of psoriasis was demonstrated in a cohort of 304 patients at three public hospitals from the metropolitan area of Barcelona.Taken together,these results provide new supportive evidence of the contribution of the CD6 lymphocyte receptor in psoriasis at both experimental and clinical levels.

关 键 词：ALCAM CD5 CD6 LYMPHOCYTE PSORIASIS 

分 类 号：R75[医药卫生—皮肤病学与性病学]